RARE Downgraded by Evercore ISI Group -- Price Target Lowers to
Ultragenyx Pharmaceutical (RARE) was downgraded by Evercore ISI Group from 'Outperform' to 'In-Line' with a new price target of $16, down from $34. The company's GF Value is $45.29, suggesting a 41.4% undervaluation. RARE has a GF Score of 68/100, indicating moderate performance with strengths in growth but weaknesses in profitability and financial strength. Insider sell activity totaled $416,870 over the last three months.
How this was made
The 30-second read
Why it matters
The downgrade reduces the upside thesis and aligns the stock with peers that have similar growth but weaker profitability.
Market read
Analyst downgrade with a 53% target cut is a notable catalyst for a small‑cap biotech, likely prompting short‑term price pressure.
What to watch
Insider sell activity is modest; the downgrade may reflect short‑term sentiment rather than fundamental deterioration.
Background
Ultragenyx Pharmaceutical (RARE) is a biotech focused on rare genetic disorders, currently unprofitable with a market cap of ~$2.6B.
Ticker impact
Evercore ISI Group downgraded Ultragenyx (RARE) to In-Line and cut the price target to $16 from $34.
Potential short‑term decline of 5‑10% as investors adjust valuations.
Analyst downgrade with a 53% target cut is a material negative catalyst for a small‑cap biotech.
Market effects
May weigh on other rare‑disease biotech stocks as valuation pressure spreads.
Limited to US biotech sector; no broader regional effect.
Low global impact; primarily relevant to US biotech investors.
Counterpoint
The stock remains undervalued per GF Value ($45.29) and could rebound if growth expectations improve.
Key entities
- AnalystEvercore ISI Group
Research firm that issued the downgrade.
- CompanyUltragenyx Pharmaceutical Inc.
Subject of the downgrade.
